Cargando…

Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST(2) in Mediating Ligand Effects

SIMPLE SUMMARY: First-generation somatostatin receptor ligands, such as octreotide, are the first-line medical therapy in acromegaly. Octreotide shows preferential binding for somatostatin receptor subtype 2 (SST(2)), while the second-generation ligand, pasireotide, has high affinity for multiple SS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amarù, Jessica, Barbieri, Federica, Arvigo, Marica, Solari, Agnese, Bajetto, Adriana, Nista, Federica, Campana, Claudia, Gaggero, Gabriele, Prior, Alessandro, Criminelli Rossi, Diego, Zona, Gianluigi, Ferone, Diego, Florio, Tullio, Gatto, Federico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069349/ https://www.ncbi.nlm.nih.gov/pubmed/33920241 http://dx.doi.org/10.3390/cancers13081816

Ejemplares similares

Octreotide-Resistant Acromegaly: Challenges and Solutions
por: Corica, Giuliana, et al.
Publicado: (2020)

Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms
por: Gatto, Federico, et al.
Publicado: (2019)

Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective
por: Nista, Federica, et al.
Publicado: (2021)

Pasireotide and octreotide in the treatment of severe late dumping syndrome
por: Mohammadi, Alireza, et al.
Publicado: (2017)

Acromegaly Management in a Tertiary Referral Center After 1 Year of the Coronavirus 2019 Pandemic: A Double Challenge
por: Gatto, Federico, et al.
Publicado: (2021)

Left Ventricular Mass Reduction by a Low-Sodium Diet in Treated Hypertensive Patients †
por: Musso, Natale, et al.
Publicado: (2020)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

Role of Chemokine Network in the Development and Progression of Ovarian Cancer: A Potential Novel Pharmacological Target
por: Barbieri, Federica, et al.
Publicado: (2010)

DOTA-Derivatives of Octreotide Dicarba-Analogs with High Affinity for Somatostatin sst(2,5) Receptors
por: Pratesi, Alessandro, et al.
Publicado: (2017)

Pasireotide Versus Octreotide in Preventing Complications After Simultaneous Pancreas-Kidney Transplantation
por: Ahopelto, Kaisa, et al.
Publicado: (2023)

Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro
por: Graillon, Thomas, et al.
Publicado: (2017)

SAT-305 Veldoreotide (COR005) Mechanisms of Action Studies: Comparison to Octreotide and Pasireotide
por: Dasgupta, Pooja, et al.
Publicado: (2020)

Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System
por: Barbieri, Federica, et al.
Publicado: (2014)

Ipsilateral Nasoseptal Flap Pedicle for Transpterygoid Approach: Technical Note
por: Anania, Pasquale, et al.
Publicado: (2021)

CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment
por: Würth, Roberto, et al.
Publicado: (2014)

Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies
por: Bajetto, Adriana, et al.
Publicado: (2020)

Cellular prion protein controls stem cell-like properties of human glioblastoma tumor-initiating cells
por: Corsaro, Alessandro, et al.
Publicado: (2016)

Inhibition of Chloride Intracellular Channel 1 (CLIC1) as Biguanide Class-Effect to Impair Human Glioblastoma Stem Cell Viability
por: Barbieri, Federica, et al.
Publicado: (2018)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease
por: Kugita, Masanori, et al.
Publicado: (2017)

Gender-Specific Efficacy Revealed by Head-to-Head Comparison of Pasireotide and Octreotide in a Representative In Vivo Model of Nonfunctioning Pituitary Tumors
por: Gulde, Sebastian, et al.
Publicado: (2021)

Clinically silent somatotroph adenomas are common
por: Wade, Alisha N, et al.
Publicado: (2011)

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study
por: Bronstein, Marcello D., et al.
Publicado: (2016)

"Present and future of immunotherapy in Neuroendocrine Tumors"
por: Albertelli, Manuela, et al.
Publicado: (2021)

Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
por: Puglisi, Soraya, et al.
Publicado: (2020)

Somatotroph Tumors and the Epigenetic Status of the GNAS Locus
por: Romanet, Pauline, et al.
Publicado: (2021)

SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly
por: Coopmans, Eva, et al.
Publicado: (2019)

Trabecular Bone Score as a Reliable Measure of Lumbar Spine Bone Microarchitecture in Acromegalic Patients
por: Nazzari, Elena, et al.
Publicado: (2022)

Change in the immunophenotype of a somatotroph adenoma resulting in gigantism
por: Thawani, Jayesh P., et al.
Publicado: (2014)

Thyrotropinoma with silent somatotroph and lactotroph adenoma during pregnancy
por: Wu, Yu-Fang, et al.
Publicado: (2022)

Sodium Intake and Target Organ Damage in Hypertension—An Update about the Role of a Real Villain
por: Nista, Federica, et al.
Publicado: (2020)

THU070 Randomized, Placebo-controlled Phase 3 Trial Protocol Assessing The Efficacy And Safety Of Octreotide Subcutaneous Depot (CAM2029) In Patients With Acromegaly
por: Ferone, Diego, et al.
Publicado: (2023)

Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021)

Repurposed Biguanide Drugs in Glioblastoma Exert Antiproliferative Effects via the Inhibition of Intracellular Chloride Channel 1 Activity
por: Barbieri, Federica, et al.
Publicado: (2019)

Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm
por: Barbieri, Federica, et al.
Publicado: (2013)

Different Effects of Human Umbilical Cord Mesenchymal Stem Cells on Glioblastoma Stem Cells by Direct Cell Interaction or Via Released Soluble Factors
por: Bajetto, Adriana, et al.
Publicado: (2017)

Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST(2) and SST(5) homo- and hetero-dimer formation
por: Treppiedi, Donatella, et al.
Publicado: (2022)

Treating age-related changes in somatotrophic hormones, sleep, and cognition
por: Vitiello, Michael V., et al.
Publicado: (2001)

Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours
por: Iacovazzo, Donato, et al.
Publicado: (2019)

Pituitary Somatotroph Adenoma-derived Exosomes: Characterization of Nonhormonal Actions
por: Zhou, Cuiqi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1bca1q2lnmo5q46gcpkqhs9eho